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ABSTRACT
Bangalore, Deepa. M.S., Department of Social and Applied Economics, Wright State 
University, 2004.
Cost Effectiveness of Treating the Metabolic Syndrome in the Uninsured in Montgomery 
County.1
treating the uninsured in cases of cardiovascular emergencies has demonstrated 
to be a large expense to the health care system, primarily borne by the society as they 
contribute to taxes/levies that support local hospitals for indigent care. Interventions to 
reduce the cardiovascular risk factors among the uninsured are expensive but have proven 
to be an effective alternative to the present situation, which is to treat them only in cases 
of emergencies. The metabolic syndrome (MS) poses a threat particularly to the 
uninsured population because of its asymptomatic nature. Detection and treatment of MS 
at its onset provides substantial clinical benefit over long periods. Economic evaluations 
of such an intervention prove to be beneficial since it would improve the quality of life of 
individuals with the syndrome, consequently improving productivity. Although the 
expense of treating the syndrome among the uninsured has to be borne by the society, the 
effectiveness generated by the cost incurred lies within the realms of what society can 
afford. This paper evaluates the potential benefits of treating this small portion of the 
population over long periods. It presents a universal model to evaluate cost-effectiveness 
of treating the uninsured with the MS, and the model is then extrapolated to the uninsured 
with MS in Montgomery County to demonstrate the effectiveness of the program. The 
model compares treatment of MS in the uninsured at the onset of the syndrome versus not 
treating them until an event that needs medical attention occurs.
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Introduction
Me ta b o lic  S yn d r o m e
The Metabolic Syndrome (MS) is a cluster of risk 
factors that are known to increase the risk of 
cardiovascular and renal diseases, and its 
consequences.1 (See Appendix A) It is also known as 
syndrome X, dysmetabolic syndrome, plurimetabolic 
syndrome, deadly quartet, or insulin resistance 
syndrome.2,3 Until recently, there was no working 
definition of MS. In 1998 and 2001, the World Health 
organization (WHO) and the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP 
III) respectively, provided a definition of the MS. The 
WHO's definition includes diabetes/impaired glucose 
tolerance with two or more of the following risk factors 
- obesity, dyslipidemia, hypertension, microalbuminuria. 
The NCEP ATP III, however, defines MS as a combination 
of three or more of the following risk factors - 
obesity, dyslipidemia, hyperglycemia, and hypertension.3
1
Although both these definitions acknowledge that 
diabetes is a component of MS, critics argue that 
diabetes is a consequence of MS rather than a component 
of MS. Lack of an explicit definition for MS has created 
confusion in the way the syndrome has been understood, 
diagnosed, and treated. Consequently, it has been the 
basis for inconsistent research about the syndrome and 
its subsequent consequences4.
Pr e v a l e n c e
A study by Lakka et al5 compared the specificity 
and sensitivity of the two definitions by studying 
middle aged Finnish men. Their results showed that the 
WHO definition had a relatively higher sensitivity and 
specificity in predicting the cardiovascular and overall 
mortality associated with MS. However, for the purpose 
of this research, the NCEP ATP III definition is used 
since the only research showing prevalence of MS in US 
adults, by Ford et al,1 uses NCEP definition. They used 
data from the Third National Health and Nutrition 
Examination Survey (NHANES III) and concluded that there 
are about 24% of US adults with the MS. The prevalence
2
increased with age and an estimated 42% of people over 
the age 60 were found to have MS. Currently, this 
appears to be the only prevalence data available for the 
US population.
Po p u la tio n
The syndrome is seldom identified and treated 
despite the fact that patients are exposed to high 
risks.6 This problem is especially important in the 
context of the uninsured due to their disconnection with 
the medical system. Studies have shown that the 
uninsured are at a higher risk for cardiovascular 
disease and all cause mortality when compared with the 
general population7. Recent studies have concluded that 
intensive treatment of hypertension, cholesterol, and 
diabetes provides excellent cost-effective ratios. 
However, the cost-effectiveness of treating the syndrome 
is not explored in the uninsured population.
Although there are many opportunities that exist to 
prevent or at least reduce the incidence of the risk 
factors of MS, the purpose of this study is to examine
3
the effects of these risk factors assuming that the 
patients already have the metabolic syndrome. In the 
population we are interested in, being uninsured reduces 
the chances of being diagnosed of any of these risk 
factors.8,9 Recognizing the fact that the uninsured go 
without being treated for the risk factors until a 
serious event occurs, this study examines the effect of 
Early Treatment of the uninsured. The study considers 
the population between the ages of 20 and 64 assuming 
that after age 64 they automatically get absorbed into 
the Medicare system.
In Montgomery County, Ohio, there are about 70,642 
uninsured between the ages of 18 and 6410. Considering 
the age-adjusted prevalence rate for MS being 24%, we 
estimated that there are about 17,500 uninsured who have 
the MS.
In a report by the US Public Interest Research 
Group,11 the uninsured pay 72% more than the insured for 
prescription drugs. Combined with the fact that most 
uninsured are the working poor (See Appendix B), the 
high costs of health care clearly discourages them from
4
following treatment regimen and also causes them to 
avoid seeing their physicians. The uninsured often wait 
untill their illness becomes severe which eventually 
drives treatment costs up to a higher level. Usually, 
these costs are recovered though cost-shifting, where 
the government uses taxpayers funds to pay for 
uncompensated care. This research attempts to determine 
the economic value in creating a safety net by providing 
preventive care to the uninsured with metabolic 
syndrome, with the intention of promoting better health. 
It is found that healthy people contribute towards 
higher productivity by increasing labor force 
participation.12,13
T r ea tm e n t  O p tio n s
Each component of MS - hypertension, dyslipidemia, 
obesity, and hyperglycemia - are serious risk factors of 
adverse cardiovascular and renal outcomes, including 
end-stage renal disease, stroke, myocardial infarction, 
and death. The presence of more than one of risk factors 
in MS amplifies the cardiovascular risks through 
aggression of the independent metabolic components.2,3 It
5
has been demonstrated that treatment directed 
specifically to the individual conditions is known to 
significantly reduce the risk of serious adverse 
outcomes.3 For the purpose of this study, we have chosen 
three main outcomes that are most prevalent and which 
can be avoided or reduced by the treatment of MS - 
stroke, myocardial infarction (MI), and end-stage renal 
disease (ESRD). Hence, the interventions to reduce the 
incidence of these consequences include intense 
treatment of one or more of the following - blood 
pressure, serum cholesterol, and blood glucose level.2'14
It is important to treat the individual risk 
factors at the onset of the syndrome. Early detection 
and treatment might help in decreasing treatment costs 
in later years due to reduction or slow down in the 
progression of major outcomes.15 Hence, the costs 
associated with Early Treatment might be offset by the 
benefits an individual receives in terms of increased 
life years with improved quality of life.23 The Early 
Treatment option is compared with current clinical 
practice, using Markov Models,16 taking into account the 
associated costs and benefits of the two options.
6
Methods
Mo d el  St r u c t u r e
Figure 1: Progression Path of Metabolic Syndrome
Figure 1 shows a simple schematic representation 
modeling the progression path of the disease. As 
depicted, there are two treatment options - 'Early 
Treatment', which starts as a primary prevention 
approach, and 'Late Term Treatment', which starts after 
an event occurs. There are three major events (Stroke, 
MI, and ESRD) that are integrated into the model to 
simulate the progression of MS. It is expected that
7
Early Treatment can reduce or delay the events and its 
outcomes when compared to Late Term Treatment. The model 
calculates the additional costs and benefits of Early 
Treatment versus Late Term Treatment.
Ma r k o v  Mo d e l
We developed a Markov model using DATA 4.0 (TreeAge 
Software, Inc., Williamstown, Massachusetts) to evaluate 
two alternatives for treating MS among the uninsured.
The Markov model's ability to incorporate time dependent 
variation of risks and probabilities, and its ability to 
represent repeated events, made it a favorable tool to 
use in this research.
Figure 2 Shows a Markov Model built in DATA 4.0.
The model assumes that at any time, all persons in the 
cohort are in a definitive state. The different states 
defined for this model are: well (perfect health), 
severe stroke, fatal stroke, mild stroke, fatal MI, non- 
fatal MI, ESRD, disability, and death. For each cycle or 
stage (average amount of time spent in each state) the 
model calculates the proportion of the cohort in each
8
health state. The cycle time chosen for the simulation 
is one year, which indicates that the Markov model 
allows for only one transition between events in one 
year. Hence, persons
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Figure 2: Health States and Treatment Options in the Markov Model
9
having a second event within one-year period are not 
accounted for in this model. For each cycle, the model 
calculates, the number of individuals who have an event 
(stroke, MI, ESRD, disability, or death), and the costs 
associated with each event, in each treatment option. 
This simulation continues until the model terminates, 
which is when the cohort reach age 65 or dies. 
Subsequently, the model can generate, for each treatment 
option, the number of people alive at the end of the 
simulation, and the quality of life of those 
individuals. These outputs can be used to calculate the 
additional lives saved and the cost per Quality Adjusted 
Life Years (QALYs) gained (See Appendix C) with one 
treatment option over the other.
Individuals in the cohort have the flexibility of 
moving from one state to another based on transition 
probabilities associated with treatment options. The 
transition probabilities then dictate the progression of 
cohorts through the different paths depending on 
severity of events and the individual's age. For 
instance, older persons have a higher probability of 
death, independent of health. Severity of events,
10
whether severe, mild, or fatal, also affects transition 
and is calculated based on a fixed proportion.19 For 
example, of those who have a stroke, a fixed proportion 
of them are assumed to have a severe, fatal, and mild 
stroke.
The model simulates the progression paths by- 
following a hypothetical cohort of uninsured who have 
MS. The model compares the two treatment options - Early 
Treatment versus Late Term Treatment, by calculating the 
incremental QALY gained and number of lives saved as the 
cohort transition from one state to another. The cohort 
is followed until they die or reach age 65, which ever 
occurs first. After age 65, it is assumed that they 
automatically get absorbed into Medicare system and 
hence will be able to get medical attention as and when 
needed. However, at the start of simulation, everyone is 
assumed to be in the 'well' state, which denotes perfect 
health. The Markov cycle is designed as a recurrent 
decision tree and hence allows any person who recovers 
completely to start in the 'well' state again. For those 
who are disabled as a result of an event, or have ESRD, 
we assumed that the disease state is not regressive, and
11
hence they cannot progress into the 'well' state again. 
In this case, the individual will remain in that state 
in recurrent cycles until the model terminates. However, 
individuals can transition to the death state at any 
time.
The cohort is characterized by age since prevalence 
of MS increases with age. Also, the incidence rates for 
the outcomes increases with age. Age-specific incidence 
rates are derived from various sources.17,18 Age-specific 
death rates are derived from US 2000 life tables and 
adjusted for specific disease conditions and insurance 
status. The Late Term Treatment group were treated with 
augmented mortality rates since the uninsured have a 
higher mortality rate, as proven by many studies.19
Death could occur due to any of the three events, 
due to disability, or any other cause. Immediate death 
does not incur costs, however, death that occurs after 
medical attention incurs costs, and as a result, the 
model emphasizes the transition based on severity of 
events. Stroke is categorized into fatal, severe, and 
mild; MI as fatal or non-fatal. Early Treatment will
12
reduce the incidence or delays the progression of 
adverse events. The model calculates effectiveness of 
one treatment option over the other, based on transition 
probabilities and utility of life measures associated 
with each treatment option.
Hea lth  Ut il it ie s
A health state provides information about an 
individual's health condition. They play an important 
role in the economic appraisal of a treatment option by 
indicating the value gained or lost by the individual 
for being in a particular state. Since patients are at 
different health states, comparisons can be made more 
efficiently, if health states are assigned a numerical 
value. To accomplish this objective, health utilities 
are assigned to health states. Each health state is 
given a utility value between zero and one to describe 
the health status of the individual. A utility value of 
1 indicates perfect health, and zero indicates death.
The utility values used for this study are derived from 
two studies. 20,23 A value of 0.5 is assigned for stroke, 
0.88 for MI, 0.61 for ESRD, and 0.46 for disability. The
13
model uses health utilities to compute the QALYs. QALYs 
are commonly used to measure the quality and quantity of 
life by taking into account the life expectancy and 
quality of remaining life years. Thus, one QALY 
represents one year of life spent in perfect health.
T ran sitio n  Pr o ba b ilities
In every cycle, individuals in the cohort may 
progress to any of the predetermined health states, 
which are estimated by the disease progression design 
based on expert opinion and various clinical trials and 
models.2'3,6'15'23'25 The transition of the cohort from one 
state to another depends on a specific occurrence rate. 
Usually, many of the clinical trials and models depict 
transition as a percentage of the population in a 
particular state. In order to simulate the progression 
of the disease in a Markov model, the percentages or 
rates have to be converted into probabilities. This is 
accomplished by using the Poisson's equation. [Poisson's 
equation: P=l-(eA-rt) where P=probability, r=rate, and 
t=time]. Since treatment starting at the onset of the 
syndrome will render fewer people in adverse health
14
states, treatment options play an important role in 
determining the transition probabilities.
In c id e n c e  Ra t e s
Incidence rates, like mortality rates are modeled 
as a function of age. When the uninsured are treated at 
the onset of the syndrome (Early Treatment), the 
incidence rates are assumed similar to the general 
population. The underlying scenario is that, once the 
uninsured are intensively treated on a regular basis, 
they no longer assume the risks of the uninsured. Hence, 
the estimates used in the analysis for the uninsured who 
undergo Early Treatment pertain to an insured 
population.
The annual age-specific incidence rate of stroke is 
derived from a study by Williams GR,17 which used 
nationwide sample of 20% of all inpatient data. MI 
incidence rates are obtained from a study by Wolf PA,21 
and ESRD incidence rates from the United States Renal 
Data System.18 These incidence rates relate to the
15
general population and hence are applied to the Early 
Treatment cohort. For the Late Term Treatment cohort, 
the incidence rates increases considerably as proven by 
many studies. The proportion by which it increases is 
derived from the results of the Heart Outcomes 
Prevention Evaluation (HOPE) Study reported by Heinig 
RE22 and The CDC Cost-effectiveness Group.23 For the Late 
Term Treatment cohort, the model uses a 44% greater 
incidence for stroke, 35% greater incidence of MI, and 
50% greater incidence of ESRD. However, treatment of 
type 1 and type 2 diabetes is found to reduce ESRD 
incidence by 71%.24
The higher incidence rates for Late Term Treatment 
cohort is due to the lack of intensive treatment. The 
difference in incidence rates is obtained by comparing 
conventional treatment to intensive treatment. 
Conventional treatment involves patients to control 
their diet, exercise, and in some cases, patients are 
treated with certain medications. Hence, the real effect 
of the Early Treatment option is subdued since the model 
assumes that the uninsured with MS help in the reduction 
of risk factors, even when not treated. The effect of
16
intensive treatment would seem more significant if the 
difference in incidence rates were a comparison of Early 
Treatment to no treatment at all, which is usually the 
condition of the uninsured, who are undiagnosed and 
untreated.
Mo r ta l it y  Ra t e s
The all-cause mortality rates for the general 
population are derived from the 2000 US Life Table.
These rates were recalculated after eliminating the 
death rates due to the four other causes of death 
(stroke, MI, ESRD, and disability) that are already 
present in the model. The mortality rates were then 
corrected for two other effects - multiple risk factors, 
and insurance status. The presence of multiple risk 
factors has proven to increase overall mortality rates. 
Previous studies25'19 have shown that diabetics have up to 
2.75 times higher risk of non-cardiovascular mortality 
rates compared to non-diabetics. Golan et al26 have used 
a standardized mortality ratio of 2.0 for all-cause 
deaths in diabetics. We assumed that people with MS have 
similar risks as the diabetics, and hence, applied a
17
mortality ratio of 2.0 to the life tables to quantify 
the additional mortality rates due to the risk factors 
of MS. This mortality rate is applied to both treatment 
options - Early Treatment and Late Term Treatment. A 
study by the Board on Health Care Services,7 showed that 
the uninsured, on average, have a 25% higher risk of 
mortality compared to the insured population.
Considering this, the excess mortality among the 
uninsured is calculated by applying the mortality ratio 
of 1.25 to the 2000 US life tables. This mortality rate 
is used for individuals undergoing Late Term Treatment 
only. The Early Treatment cohort is conceived to be 
similar to the insured population, because of their 
ability to receive treatment on a regular basis and have 
access to needed care.
S e v e r it y  o f  E v e n t s
In clinical practice, treating an event has 
different costs associated with it depending on its 
severity. For example, a stroke that causes a person to 
become disabled will have a higher treatment cost than a 
stroke that will allow the person to get back to perfect
18
health. In the case of stroke that causes disability, 
considerable expense occurs for a longer period of time. 
We therefore apportioned events into different 
categories based on severity, which portrays 
disproportionate costs. A fixed proportion of the cohort 
having an event is expected to have either a mild, 
severe, or a fatal event. The fractions for severity of 
stroke and MI are derived from a study by Elliot et 
al.19 Stroke is characterized into fatal, severe, and 
mild. Of the cohort having a stroke, 25% of them have a 
severe stroke which may led to long term disability, 25% 
are fatal, and 50% are minor stroke. Mild stroke victims 
are assumed to revert back to perfect health, and fatal 
stroke victims incur no costs since death occurs before 
any medical attention is provided. MI is categorized 
into fatal or non-fatal. A fixed 35% of the patients are 
expected to have a fatal MI.
Health insurance status varies the severity of 
events. Being uninsured and hence not receiving 
treatment for the risk factors increases the severity of 
events. Thus, in the Late Term Treatment group, there is 
a higher incidence of fatal events. A number of clinical
19
trials have evaluated the effectiveness of treating risk 
factors by comparing cohorts who have received 
medication versus a placebo. The West of Scotland 
Coronary Prevention Study (WOSCOPS) and the Heart 
Outcomes Prevention Evaluation (HOPE) study have 
indicated that medication reduces stroke mortality and 
MI mortality by 19% and 31% respectively. 27,28 These 
rates are used as increased event fatality rates for the 
Late Term Treatment cohort. The mortality rates for ESRD 
are fixed at 27% annually.26 Mortality rates for 
disability are derived from the United States Social 
Security Administration database.29
Although individuals with ESRD or disability are at 
increased risk of having another event such as stroke or 
MI, these effects have not been considered in the model, 
as the event probabilities in such scenarios have not 
been well quantified. As a result, ESRD and disability 
are modeled as recurring states, which indicate that a 
person with disability or ESRD cannot transition into 
other states, and thereby, will continue to be in that 
state until the model terminates. As mentioned earlier,
20
the model terminates when individuals reach age 65 or
die.
C o s t s  o f  T r ea tm e n t  and  C o m p lic a tio n s
All costs used in the model are derived from 
medical literature. Since this population is high risk, 
it is assumed that the cohort receives intensive 
treatment for any of the risk factors of MS they may 
have. Intensive treatment consequently provides better 
outcomes and is proven to significantly reduce event 
rates. In addition, intensive treatment is more 
expensive than conventional treatment, and hence, the 
costs and outcome measures of intensive treatment 
considered for this study is to quantify the best value 
gained in treating uninsured individuals with MS. 
Consequently, utility values and disease progression 
rates in the Early Treatment cohort assume values that 
occur due to intensive treatment.
The cost of intensive treatment of hypertension, 
hyperlipedemia, and blood glucose was derived from two 
cost-effectiveness studies23,25 that expressed costs in
21
1997 and 1995 US dollars respectively. This cost 
included annual costs of medication, physician visits, 
and the required laboratory tests. Cost of treating the 
individual risk factors of MS is pertinent to the Early 
Treatment cohort alone, since the Late Term Treatment 
group is assumed to get treatment only for an event 
occurring as a result of MS. The cost of events depends 
on its severity. Treating severe events are more 
expensive than treating mild events. The data for costs 
of treating events was derived from a study by Elliott 
et al.19 All costs were adjusted for inflation based on 
the US Bureau of Labor Statistics to represent 2001 US 
dollars. The costs of treating risk factors and events 
are listed in Table 1.
Table 1: Base Case Parameters
Variable Value
Age 30
Cost of Disability $46,327
Cost of ESRD $44,764
Cost of Fatal MI $17,998
Cost of Fatal Stroke $26,710
22
Cost of Mild Stroke
Cost of Non-fatal MI
Cost of Non-fatal Stroke
Cost of Hyperlipidemia Treatment
Cost of Diabetes Treatment
Cost of Hypertension Treatment
Probability of ESRD
Probability of MI
Probability of Stroke
Probability of ESRD (uninsured)
Probability of MI (uninsured)
Probability of Stroke (uninsured)
Probability of death related to age,
gender, and race
Probability of death related to age, 
gender, and race (uninsured)
$13,354 
$35,996 
$53,459 
$1,543 
$1,157 
$661 
0.00024 
0.00544 
0.000716 
0.000312 
0.007072 
0.001032
0.001328
0.0013047
Fatal events do not incur any cost due to the 
underlying scenario that fatal (immediate death) events 
do not incur costs. However, death occurring after 
medical attention incurs cost, and is accounted for in
23
the analysis. The cost of treating ESRD is $44,764, 
derived from the United States Renal Data System.30
O u tc o m e s
The primary purpose of economic evaluations in 
healthcare is to be able to rank interventions based on 
outcomes.31 In order to compare the treatment options, 
two outcomes measure were chosen to represent the value 
gained or lost in choosing one treatment option over the 
other. They were - cost/QALY gained, and number of lives 
saved. These two outcome measures make it possible to 
compare the treatment options as it provides a clear 
picture of the lasting health benefits of each treatment 
option. Hence, the choice of an outcomes measure is 
important as it exclusively represents the results of a 
cost-effectiveness study. Cost per QALY gained shows the 
additional cost needed to generate one year of perfect 
health. 32 The number of lives saved depicts the 
additional number of people alive as a result of the 
treatment option. Using these outcomes, treatment 
options can be compared and prioritized based on its 
cost to effectiveness ratios. Hence, it is important to
24
access the monetary value of the outcomes so that policy 
makers can decide what options to consider so that it 
will yield a greater social benefit. The costs and QALYs 
are discounted at 3% annual rate and are expressed in 
2001 US dollars.
25
Results
Ba s e -c a s e
As a base-case scenario, we followed a cohort of 
30-year-olds, since the uninsured between the ages 20-34 
make up 56% of the low-income uninsured population,33 
and 49% of the total uninsured population. Early 
Treatment of MS risk factors resulted in a $13,953 per 
QALY gained for treatment of hypertension, $25,929 for 
treatment of Diabetes, and $35,331 per QALY gained for 
hyperlipidemia treatment. At the end of the simulation 
(when the cohort reached age 65), the cumulative medical 
cost per person in the Early Treatment cohort was 
$10,960, $15,008, and $27,816 higher than the Late Term 
Treatment group for hypertension, diabetes, and 
hyperlipidemia treatment respectively.
Treating MS in younger people was found to save 
more lives compared to treating MS in older people. The 
additional number of lives saved with Early Treatment
26
for 20 year old cohort was 10.84% and dropped to 5.47% 
in the 60 year old cohorts, suggesting that the onset 
and treatment of MS at an older age results in a higher 
death rate due to co-morbidities. Figure 3 shows the 
additional number of lives saved due to Early Treatment 
in different age groups. Thus, treating MS at its onset 
saves more lives in younger patients than in older 
patients.
Figure 3: Cumulative Event Rates by Treatment Groups
Considering this, we can conclude that although the 
cost of treatment does not lead to a cost saving (where 
the cost-effectiveness ratio, defined as the incremental
27
cost cumulative medical costs divided by the change in 
QALYs, would have been negative), it helps in extending 
the life of individuals. The cost saving is not apparent 
as there are more people in the Early Treatment group 
who live longer and hence would consume more health 
care. This is explored in greater detail in the 
sensitivity analysis.
Comparing the two cohorts, we found that there was 
a significant decrease in the probability of fatal 
stroke, fatal MI, and ESRD in the Early Treatment group 
when compared to the Late Term Treatment group. The p- 
values for each of those events were 0.056, <.0001, and 
0.030 respectively. This analysis was performed using 
the Statistic Package for Social Science (SPSS 10.0.1; 
SPSS Inc., Chicago, 111). T-tests were performed to 
compare the probabilities of events in the two treatment 
groups. Figure 4 shows the cumulative incidence of 
events (including death) by treatment group over time. 
The upper curve represents the event rate of the Early 
Treatment and the lower curve represents the cost of 
treating the Late Term Treatment cohort. As shown in the
28
figure, the event rates are higher in the Late Term 
Treatment group as the age of the cohort increases.
Figure 4: Additional number of lives saved with Early 
Treatment
S e n s it iv it y  A n a lysis
One-way sensitivity analysis (where only one 
parameter is varied at a time) was performed for 
treatment of hypertension, diabetes, and hyperlipidemia 
by varying parameters such as age, cost, and incidence 
rates, and mortality rates of some events. The
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parameters used in the sensitivity analysis are 
presented in Table 2.
Table 2: Parameters Used in Sensitivity Analysis
Base-case Range Reference
Age 30 20-64 NA
Treatment costs, $:
Hypertension 661 266-775 23
Diabetes 1157 1029-1285 25
Hyperlipidemia 1543 600-2100 23, 34
Increase in event rate for LTT* cohort, %:
Stroke 44 33-69 35, 36
MI 35 22-29 35, 36
ESRD 50 26-71 24, 25
*LTT = Late Term Treatment
Varying Age
As shown in Table 3, the incremental cost- 
effectiveness (the additional cost divided by additional 
effectiveness) of Early Treatment over Late Term 
Treatment decreases as age increases, but increases for
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the 60 year old cohort. The best cost-effectiveness is 
obtained by treating people between ages 50-59. This is 
true for treatment of all the three risk factors 
(hypertension, diabetes, and hyperlipidemia). It may be 
recalled that the additional number of lives saved with 
Early Treatment relative to Late Term Treatment 
decreases as age of the cohort increases. Tying this 
effect of Early Treatment with its incremental cost- 
effectiveness, we can conclude that cost-effectiveness 
is higher for younger cohorts, as they tend to live 
longer and consequently use more medical care.
Table 3: Incremental Cost-effectiveness of Early Treatment 
(Cost/QALY Gained)
Treatment age Hypertension Diabetes Hyperlipidemia
20 $17,012 $31,115 $42,077
30 $13,953 $25,929 $35,331
40 $10,953 $21,234 $29,226
50 $8,582 $18,215 $25,703
60 $11,684 $27,788 $40,306
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Varying Costs
Using the lowest cost of treatment yielded an 
incremental cost-effectiveness of $4,325/QALY gained for 
treating hypertension, $22,840 for diabetes, and 
$12,424/QALY for treating hyperlipidemia in a cohort of 
30-year-old patients. Using the upper limits for the 
treatment costs, the incremental cost-effectiveness was 
found to be 16,667/QALY gained for treating 
hypertension, $29,033/QALY gained for treating diabetes, 
and $48,795/QALY gained for treating hyperlipidemia. 
Although the incremental cost-effectiveness ratio varies 
with the treatment cost of risk factors, the results 
obtained were within the acceptable range 
($40,000/QALY). (See Appendix C) The upper limit of 
cost-effectiveness of treating hyperlipidemia 
($48,795/QALY), although slightly over the conventional 
limit, has been acceptable in many of the federally 
mandated projects, such as use of passenger side air 
bags (69,000/QALY gained) and intensive neonatal care 
($47, 000/QALY) .37
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Varying Event Rates
Varying the event rates in the Late Term Treatment 
group, the cost-effectiveness of Early Treatment of 
hypertension ranged from 10,656/QALY to $17,587/QALY, 
diabetes ranged from 18,464/QALY to 28,126/QALY, and 
treatment of hyperlipidemia ranged from 29,329/QALY to 
42,792/QALY. This demonstrates that Early Treatment is 
more cost-effective if the incidence rates of adverse 
events are lowered to a greater extent, compared to the 
Late Term Treatment group. This justifies our choice of 
intensive treatment of risk factors in the uninsured 
population with MS, rather than the conventional 
treatment.
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Limitations
The limitations in this study are primarily due to 
lack of sufficient data on the combined effects and 
costs of all the risk factors of MS. Furthermore, there 
are relatively fewer clinical trials performed among the 
uninsured, which adds to our limitation in terms of data 
and true effects of treatments, as we have extrapolation 
the results of the general population to the uninsured. 
The effectiveness of not treating uninsured population 
was derived from published data of clinical trials, 
which used placebo to determine the effect of no 
treatment. This naturally undermines our cost- 
effectiveness estimates due to the placebo effect. A 
placebo effect is a mysterious positive effect in a 
patient's health when treated with placebo. Likewise, 
when comparing the two treatment options, the difference 
in the incidence rates of events is obtained from a 
study comparing moderate treatment and intensive 
treatment. Moderate treatment includes diet and drugs,
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which is known to provide some amount of health 
benefits. In the model, although we consider the Late 
Term Treatment group to have no treatment at all, we 
have in fact incorporated the effects of moderate 
treatment. Hence the analysis would provide better cost- 
effectiveness ratios if the uninsured in the Late Term 
Treatment group were modeled as not having any kind of 
moderate care.
Apart from therapies directed at the individual 
risk factors of MS, lifestyle changes have also been 
commonly recommended for patients with MS to help reduce 
adverse outcomes. However, this model takes into account 
specifically the clinical costs and effectiveness of 
treating MS assuming that patients do need medication to 
control their risk factors. The model also assumes that 
patients follow treatment regimen and hence we did not 
assess the influence of treatment discontinuation or 
non-compliance issues. Furthermore, the treatment of MS 
is assumed to start at the onset of the syndrome, rather 
than at clinical diagnosis. Hence, the model does not 
account for the development of clinical complications 
before diagnosis and treatment, and assumes that there
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are no other co-morbidities present at the start of the 
treatment regimen.
In this model, due to data limitations, we have 
assumed that the probability of having an event is 
independent of previous events. Realistically, 
recurrence rates are higher in people who have already 
had an event. The cycle time, being one year, does not 
account for recurrent events that occur within a one- 
year period. Also, the model does not permit transition 
of people who are disabled or have ESRD to any other 
state other than death. This assumption was primarily 
due to lack of data on the transition probability and 
utility of life measures for those who were already 
disabled or have ESRD and had another event.
In modeling the risk factors of MS, we have 
approximated the costs and effects of treating 
dyslipidemia with costs and effects of treating 
hyperlipidemia. Hyperglycemia is evaluate as diabetes 
mellitus, as a study by Alexander TM et al38 
demonstrated that 86% of diabetic patients, age 50 and 
over, have MS.
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Incidence and progression of risk factors of MS are 
modeled to be a function of age. However, they are also 
dependent on gender, race, and family history. For 
example, African American women are found to have 57% 
higher prevalence of MS compared to men. We have not 
incorporated the effects of some of these demographic 
differences in the analysis.
In terms of determining the cost of treating the 
individual risk factors of MS, costs of medication, 
physician visits, and tests for each of the risk factors 
are incorporated in the model. It can be argued that 
since people with MS may have more than one of these 
risk factors, physician visits may be common to all the 
risk factors they may have. In the model, physician 
visits is associated with the risk factor and not the 
individual. This may have led to double counting of cost 
of treatment of risk factors, which again underestimates 
the cost-effective analysis results.
The cost of each treating risk factors and the 
events are derived from studies that used the 1996 or 
1997 dollars. These cost, although have been adjusted
37
for inflation to represent 2001 dollars, it does not 
account for changes in treatment criteria, or the 
improvement in technology that helps deliver more 
economical care. In addition, health care inflation is 
found to be higher than the normal inflation rate, but 
this has not been taken into account in this analysis.
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Conclusions
MS in the uninsured is an issue that is not 
sufficiently investigated, and as its prevalence is 
increasing, more research in this area would help to 
better understand the syndrome and its consequences. The 
risk factors of MS, especially hypertension and 
diabetes, are of serious concern as a large number of 
those having the syndrome are unaware of its presence. 
Hence, a greater value lies in increasing awareness of 
MS risk factors. It is found that 31.6% of hypertensives 
and 34.6% diabetics are unaware of their condition.39
The cost-effectiveness results demonstrate that the 
cost/QALY gained in treating MS risk factors in the 
uninsured lie within the conventionally accepted 
thresholds. Also, our sensitivity analysis supports our 
initial results, thereby suggesting that our model was 
sufficiently robust. Our results showed that treating MS
39
in people between ages 50-59 is most cost-effective, but 
the number of lives saved is the highest for younger 
cohort.
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Appendices
A ppen d ix  A - The M etab o lic  Syn drom e
According to the NCEP definition, person having 
three or more of the following criteria is clinically- 
diagnosed as having MS:
- Abdominal obesity: waist circumference >102 cm
in men and >88 cm in women;
- Hypertriglyceridemia: >150 mg/dL (1. 69 mmol/L);
- Low high-density lipoprotein (HDL) cholesterol:
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL 
(1.29 mmol/L) in women;
- High blood pressure: >130/85 mm Hg;
- High fasting glucose: >110 mg/dL (>6.1 mmol/L).
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A ppen d ix  B - H ea lth  In su ran ce
The United States is the only industrialized county 
in the world without universal health coverage. In 2002, 
there were more than 43.6 million people1 (15.2% of the 
population) who were without any form of health 
coverage. The concept of health insurance emerged in the 
early 20th century and employers used it to attract 
workers with the fact that it would protect workers 
against unforeseen costs of medical care, and would also 
help them receive preventive care so that they stay 
healthy longer which would in turn increase 
productivity.2 Today, majority of the workers are 
privately insured through their employers. However, many 
small businesses do not offer health insurance coverage 
to its employees. Hence, the majority of the uninsured 
tend to be workers with low income. In 1965, when 
Medicare and Medicaid were introduced, the intent was to 
provide insurance to the elderly and the indigent.
1 U .S.Department of Commerce, Economics and Statistics 
Administration. U.S. CENSUS BUREAU. Health Insurance Coverage in 
the United States: 2002. Issued September 2003. Available at:
http://www.census.gov/prod/2 0 03pubs/p6 0-2 2 3 .pdf
2 Paul Starr. The Social Transformation of American Medicine. Basic 
Books, New York NY; 1982.
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Medicare helps to cover the elderly, and Medicaid helps 
to cover the indigent and the disabled. Many poor people 
do not qualify for the Medicaid program since the 
criteria are very stringent, so much so, that the 
poorest of people (incomes below 200% of the federal 
poverty level) are refused coverage and only the 
severely disabled get coverage.3 There are options for 
people to buy their own plans. Individual plans usually 
have high premiums or offer limited benefits, which does 
not make it appealing to the low-income people. Hence, 
the low-income people are left with no choice but 
continue being uninsured.
The consequences of being uninsured are tremendous. 
A report by The Kaiser Commission on Medicaid and the 
Uninsured3 shows that the uninsured receive less 
preventive care, forgo needed care (because of cost), 
and hence lead a sicker life and have higher mortality 
rates. Although it has been proven that the insured use
3 Jack Hadley. Sicker and Poorer - The Consequences of Being 
Uninsured: A Review of the Research on the Relationship between 
Health Insurance, Medical Care Use, Health, Work, and Income. 
Medical Care Research and Review. June 2003; Vol. 60, No. 2, 
Supplement. Available at: http://www.kff.org/content/2003/4115/
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more medical care,4 (as the uninsured tend to avoid 
medical care) the uninsured accumulate financial costs, 
which are passed on to the society. Since the uninsured 
usually use the emergency department visits for needed 
care, the cost of care increases dramatically, as ER 
visits are the most expensive form of care. It is found 
that the uninsured use emergency department visits four 
times more than the insured. On average, it was 
estimated that the uninsured pay only about a quarter of 
their medical cost out-of-pocket. Incidentally, these 
rates are much higher than what an insured person pays, 
since the co-pays through health insurance is lower than 
what a person would have to pay without insurance. 
However, about 35% of the total medical cost in treating 
the uninsured is reported as uncompensated.
There are some striking facts about the improvement 
in health and consequently the rise in the cost of 
treating the uninsured. It is estimated that if the
4 Jack Hadley and John Holahan. Covering the Uninsured: How Much 
Would It Cost?. Health Affairs (Web Exclusive). June 4, 2003. 
Available at:
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uninsured had access to better care, it would help them 
increase their earnings by 10-30%. It would also 
decrease hospitalization rates and mortality rates 
significantly. Hence, one policy option suggested by 
many researchers is to extend Medicare benefits to the 
uninsured. This is the premise of our study since we are 
proposing the allocation of public funds to treat the 
uninsured to reduce adverse outcomes on a long-term 
basis. Furthermore, the uncompensated costs of treating 
the uninsured will reduce substantially. Since the 
uninsured will be diagnosed at an early stage, which 
will help decrease progression of diseases, the number 
of emergency department visits will consequently 
decrease. When consistent preventive care and access to 
medication continues, expensive and unexpected 
procedures can be avoided, which in the long run, will 
be beneficial. The current approach of not providing 
preventive care for the uninsured, and hence having a 
cost saving, is deemed to be 'shortsighted',5 as the
http://www.healthaffairs.org/WebExclusives/Hadley_Web_Excl_060403.h 
tm
5 Marieke D. Schoen et. al. Impact of the Cost of Prescription 
Drugs on Clinical Outcomes in Indigent Patients With Heart Disease. 
Pharmacotherapy. 2001; 21(12): 1455-1463
45
society will have to bear the expenses of delayed 
medical care and poor disease control, which are more 
expensive to treat.
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A p p en d ix  C - q a l y s
Health economists and health professionals at large 
have found it very difficult and also have been hesitant 
in measuring the value of an individual's health in 
monetary terms. The argument here is whether to value a 
rich person's life differently than a poor person's 
life. This consequently becomes more of an ethical issue 
rather than an economics issue. Unless there is some 
level ground to measure health benefits, there is always 
going to be a discrepancy in the way health care 
interventions and developments are valued. So far, the 
quality-adjusted life-year (QALY) has been widely 
accepted in the health community as it assesses both the 
quality and quantity of life rather than having a dollar 
amount on life. Critics of the cost per QALY method 
argue that treatment for acute conditions may not be 
eligible since they might not show a net societal 
benefit, which results in inequality, since this method 
would suggest accepting programs that benefit more
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people than programs that benefit only a few.6 The 
other method commonly used in such scenarios is known as 
the 'Willingness to Pay' (WTP), which directly assigns a 
value to health in monetary terms and does not identify 
an upper limit to health benefits. The limitation of 
this method is that it cannot be used to measure many 
different health scenarios without surveying individuals 
for each of those scenarios.
Quality-adjusted life-year accounts for 
differential impacts of one intervention over another 
both in terms of quality and quantity of life gained.
The rationale for using both quality and quantity of 
life is because they are two basic components that 
interventions are designed to enhance. Mathematically, a 
QALY is derived by multiplying life expectancy (a 
quantity measure) and health utility (a quality measure) 
of the remaining life-years. Although the quantity of 
life, or life expectancy, is easily measured, quality of 
life calls for more calculations. There are a number of
6 Mohan V. Bala; Gary A. Zarkin. Are QALYs an Appropriate Measure 
for Valuing Morbidity in Acute Diseases? Health Econ. 2000; 9: 177- 
180
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ways to measure the quality of life, or health utilities 
- standard gamble, time trade-off, and visual analog 
scales are the ones that are commonly used methods. In 
the visual analog scales method, patients rate their 
health status on a scale of zero to one, one being 
perfect health. In time trade off method, patients 
indicate the number of years of perfect health that is 
equivalent to the number of years in a particular health 
state. In standard gamble method, patients propose their 
willingness to accept the risk of death in order to 
shift from a specific health state to perfect health. 
Hence utility value of zero represents death and one 
represents perfect health. However, some health states 
may be considered worse than death and may carry a 
negative score.
Hence, QALYs provide a uniform ground for comparing 
different health care interventions in terms of 
maximizing the benefits of patients. Using cost per QALY 
identifies whether the cost for the intervention exceeds
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the value gained.7 Prioritizing different interventions 
can be done by comparing the cost per QALY of all the 
interventions and choosing the one that has a lower cost 
per QALY. The commonly accepted threshold is $40,000 per 
QALY.7 The justification for this amount is due to the 
fact that dialysis costs $40,000 per QALY, and Medicare 
covers the costs of dialysis patients. Since Medicare is 
a federally funded program and consists of -taxpayers' 
contributions, it is assumed that society believes that 
a $40,000 per QALY threshold is beneficial. However, 
there have been cases where interventions that exceed 
this threshold have also been chosen. In essence, QALYs 
provide a tool for policymakers when resource allocation 
decisions need to be made between competing medical 
services.
7 Gold, MR, Siegel JE, Russell LB and Weinstein, MC. (eds.) Cost- 
effectiveness in Health and Medicine. New York: Oxford University 
Press. 1996
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A ppen d ix  D - M arkov M od els , S e n s itiv ity  A n a ly s is , and DATA 
4.0
Economic evaluation tools are becoming increasingly 
common in clinical decision making to help measure 
outcomes of various clinical strategies. Since cost is a 
determining factor in most health care interventions, 
cost-effective analysis using decision models has become 
popular as it provides a simplified structure to assist 
in determining the most effective option. Markov models, 
also known as state transition models, are commonly used 
for such analyses. Markov models are particularly 
helpful for several reasons - it helps in building the 
analytical structure representing the important events 
that repeat over time, synthesizes effectiveness data 
and compares it to the costs associated with it, and 
calculates the desired output. A Markov model consists 
of a finite set of states, which represents the 
different health conditions that a member of the cohort 
can possibly assume. At any given time, a cohort member 
can assume only one possible state. Each state is 
associated with a utility value, which helps in 
determining or describing the health outcomes of a
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particular state. Each state is linked to one another 
depending on the probability of their occurrence. The 
probability of occurrence is also called transition 
probabilities, which help in transitioning the members 
of the cohort among possible states during a single 
cycle. A cycle is defined as a specified interval of 
time (that is clinically meaningful) during which a 
transition occurs. At the beginning of the simulation, 
it is often assumed that the entire cohort starts in the 
same state. There are three types of states in a Markov 
model - absorbing state, temporary state, and transient 
states. Absorbing states are essential to help terminate 
the simulation. It typically determines the end state 
that is defined by the study. Usually, the death or 
disability is an absorbing state in cases where the 
model spans the entire life of a patient. On the other 
hand, if the cycle length is short, typically for models 
studying short-term impact, there may be other 
termination states. A temporary state is a state that 
models a short-term event, which typically does not last 
for more than one cycle. A tunnel state is a set of 
temporary states such that one state occurs after 
another in a predefined fashion, and lasts for more than
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one cycle. Transition probabilities can be constant or 
time-dependent. The incidence of stroke can be dependent 
on age and hence time-dependent, whereas, transition 
from disability to death may be constant.
The modeling technique used to simulate the 
progression of the metabolic syndrome is performed by 
cohort simulation using DATA 4.0 software. Cohort 
simulation is the most intuitive representation of the 
Markov process, where a cohort of patients transition 
through the model simultaneously. DATA uses a graphic 
decision tree representation of a Markov model (also 
known as 'Markov-cycle tree') and integrates the 
principle elements for the simulation, which include, 
transition probabilities, cycle length, and utility 
value and/or cost of being in a health state. The cohort 
cycles through the different states in the model, until 
they reach a termination criterion specified by the 
design of the simulation. One assumption of the Markov 
model, also known as the Markovian property, is that the 
current health states are independent of previous health 
states. In other words, patients' history cannot 
determine their transition from one health state to
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another; their transition will be determined by the 
transition probability associated with the state. 
However, if previous histories have to be implemented in 
the model, a special subset has to be created for the 
cohort with a particular utility.
DATA has a built in discounting function that 
discounts both costs and utilities. Discounting is 
essential because it takes into account the present 
value of future costs and benefits. It is based on the 
fact that a given amount of resources is less valuable 
in the future than at present. Hence a Markov cycle tree 
combines the simplicity of a decision tree and realistic 
representation of clinical problems.
DATA also helps in performing sensitivity analysis. 
When initial values are assigned to variables, the most 
plausible values are taken into account. Usually, there 
is always a possibility of a range of values that may 
fit the unknown quantities. If the range of assumptions 
is accounted for in the model, it increases the 
robustness of a model. Hence, the practical reason for a 
sensitivity analysis is to obtain a range of values that
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would help in reducing the uncertainty associated with 
the assigning initial values (base case) to variables.
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Data
Tables used in the Markov Model:
Age, Gender, and Race Related Mortality Rates
Age m H * LTT*
20 0.001025 0.000938
21 0.001139 0.00108
22 0.001215 0.001175
23 0.001241 0.001208
24 0.001231 0.001195
25 0.001199 0.001149
26 0.001191 0.001139
27 0.001195 0.001144
28 0.001223 0.001179
29 0.001275 0.001244
30 0.001329 0.001305
31 0.001403 0.001397
32 0.001511 0.001532
33 0.001659 0.001717
34 0.001833 0.001935
35 0.001936 0.002024
36 0.00213 0.002266
37 0.00235 0.002541
38 0.002602 0.002856
39 0.002886 0.003211
40 0.003171 0.003558
41 0.003491 0.003958
42 0.003839 0.004393
43 0.004229 0.004881
44 0.004665 0.005426
45 0.004246 0.00448
46 0.004786 0.005155
47 0.005352 0.005863
48 0.00592 0.006573
49 0.006494 0.00729
50 0.005276 0.004932
51 0.00595 0.005774
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52 0.006694 0.006704
53 0.007548 0.007772
54 0.00854 0.009012
55 0.008975 0.009209
56 0.010285 0.010847
57 0.011713 0.012632
58 0.013213 0.014507
59 0.014793 0.016482
60 0.015051 0.016108
61 0.017055 0.018613
62 0.019201 0.021295
63 0.021451 0.024108
64 0.023815 0.027063
65 0.023535 0.025441
*ET = Early Treatment, LT = Late Term Treatment
Stroke Incidence Rates Stroke Mortality Rates
Age Probability Age Probability
20 0.00031 20 3.88E-05
35 0.00092 35 0.000115
45 0.00293 45 0.000366
55 0.00822 55 0.001028
65 0.02028 65 0.002535
Stroke Incidence Rates in Uninsured Stroke Mortality Rates in Uninsured
Age Probability Age Probability
20 0.000446 20 5.58E-05
35 0.001325 35 0.000166
45 0.004219 45 0.000527
55 0.011837 55 0.00148
65 0.029203 65 0.00365
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Ml Incidence Rates Ml Mortality Rates
Age Probability Age Probability
45 0.0076 45 0.00133
50 0.0178 50 0.003115
60 0.026 60 0.00455
65 0.0326 65 0.005705
Ml Incidence Rates in Uninsured Ml Mortality Rates in Uninsured
Age Probability Age Probability
45 0.00988 45 0.001729
50 0.02314 50 0.00405
60 0.0338 60 0.005915
65 0.04238 65 0.007417
ESRD Incidence Rates ESRD Mortality Rates
Age Probability Age Probability
25 0.000178 25 0.00002403
30 0.000242 30 0.00003267
35 0.000292 35 0.00003942
40 0.000412 40 0.00005562
45 0.000636 45 0.00008586
50 0.000954 50 0.00012879
55 0.001412 55 0.00019062
60 0.001952 60 0.00026352
65 0.002524 65 0.00034074
ESRD Incidence Rates in Uninsured 
Age Probability
ESRD Mortality Rates in Uninsured 
Age Probability
25 0.00022962 25 0.000036045
30 0.00031218 30 0.000049005
35 0.00037668 35 0.00005913
40 0.00053148 40 0.00008343
45 0.00082044 45 0.00012879
50 0.00123066 50 0.000193185
55 0.00182148 55 0.00028593
60 0.00251808 60 0.00039528
65 0.00325596 65 0.00051111
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